

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**22-278**

**LABELING**

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use MembraneBlue™ 0.15% safely and effectively. See full prescribing information for MembraneBlue™ 0.15%.

MembraneBlue™ 0.15% (trypan blue ophthalmic solution)

Initial U.S. Approval: 2004

-----Indications and Usage-----

- For use as an aid in ophthalmic posterior surgery;
- Facilitating removal of epiretinal tissue. (1)

-----Dosage and Administration-----

- Prior to injection of MembraneBlue™ 0.15% perform a 'fluid-air exchange'; Carefully apply MembraneBlue™ 0.15% to epiretinal membranes using a blunt cannula; Remove all excess dye  
Or
- Inject MembraneBlue™ 0.15% directly in a BSS filled - vitreous cavity; Wait 30 seconds; Remove all excess dye. (2)

-----Dosage Forms and Strength-----

- MembraneBlue™ 0.15% (trypan blue ophthalmic solution) in a volume of 0.5 mL. (3)

-----Contraindications-----

- Insertion of a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL). (4)

-----Warnings and Precautions-----

- Excessive staining: Excess MembraneBlue™ 0.15% should be removed from the eye immediately after staining. (5)

-----Adverse Reactions-----

- Discoloration of high water content hydrogen intraocular lenses;
- Inadvertent staining of the posterior lens capsule and vitreous face. (6)

To report SUSPECTED ADVERSE REACTIONS contact Dutch Ophthalmic, USA at 1-800-75-DUTCH or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

-----Use in Specific Populations-----

- Trypan blue should not be given to a pregnant woman. (8)

Revised 1/2009

---

**FULL PRESCRIBING INFORMATION:  
CONTENTS\***

- |                                |  |
|--------------------------------|--|
| 1. Indications and Usage       | 8.4 Pediatric use  |
| 2. Dosage and Administration   | 8.5 Geriatric use  |
| 3. Dosage Forms and Strength   | 11. Description  |
| 4. Contraindications           | 12. Clinical Pharmacology                                    |
| 5. Warnings and Precautions    | 12.1 Mechanism of Action                                     |
| 6. Adverse Reactions           | 13. Nonclinical Toxicology                                   |
| 8. Use in Specific Populations | 13.1 Carcinogenesis, mutagenesis,<br>impairment of fertility |
| 8.1 Pregnancy                  | 16. How Supplied/Storage and Handling                        |
| 8.3 Nursing mothers            |  |
- \*Sections or subsections omitted from the Full Prescribing Information are not listed.
-

**FULL PRESCRIBING INFORMATION:  
CONTENTS\*****1. Indications and Usage**

MembraneBlue™ 0.15% is indicated for use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue.

**2. Dosage and Administration**

Before injection of MembraneBlue™ 0.15% perform a 'fluid-air exchange', i.e. filling the entire vitreous cavity with air, to prevent aqueous dilution of MembraneBlue™ 0.15%. MembraneBlue™ 0.15% is carefully applied to the retinal membrane using a blunt cannula attached to the MembraneBlue™ 0.15% syringe, without allowing the cannula to contact or damage the retina. Sufficient staining is expected on contact with the membrane. All excess dye should be removed from the vitreous cavity before performing an air-fluid exchange, to prevent unnecessary spreading of the dye. MembraneBlue™ 0.15% can also be injected directly in a BSS filled vitreous cavity (instead of injecting under air). Clinical use demonstrated that, after complete vitreous and posterior hyaloid removal, sufficient staining is achieved after 30 seconds of application under BSS.

MembraneBlue™ 0.15% is intended to be applied directly on the areas where membranes could be present, staining any portion of the membrane which comes in contact with the dye. The dye does not penetrate the membrane.

**3. Dosage Forms and Strength**

MembraneBlue™ 0.15% (trypan blue ophthalmic solution) is supplied in 2.25 mL syringes filled to a volume of 0.5 mL.

**4. Contraindications**

MembraneBlue™ 0.15% is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye. The dye may be absorbed by the IOL and stain it.

**5. Warnings and Precautions****Excessive staining**

It is recommended that after injection all excess MembraneBlue™ 0.15% be immediately removed from the eye.

**6. Adverse Reactions**

Adverse reactions reported following use of MembraneBlue™ 0.15% include discoloration of high water content hydrogen intraocular lenses (see Contraindications) and inadvertent staining of the posterior lens capsule and vitreous face. Staining of the posterior lens capsule or staining of the vitreous face is generally self limited, lasting up to one week.

**8. Use in Specific Populations****8.1 Pregnancy**

Teratogenic Effects: Pregnancy Category C. Trypan blue is teratogenic in rats, mice, rabbits, hamsters, dogs, guinea pigs, pigs, and chickens. The majority of teratogenicity studies performed involve intravenous, intraperitoneal, or subcutaneous administration in the rat. The teratogenic dose is 50 mg/kg as a single dose or 25 mg/kg/day during embryogenesis in the rat. These doses are approximately 4,000- and 2,000-fold the maximum recommended human dose of 0.75 mg per injection based in a 60 kg person, assuming that the whole dose is completely absorbed. Characteristic anomalies included neural tube, cardiovascular, vertebral, tail, and eye defects. Trypan blue also caused an increase in post-implantation mortality, and decreased fetal weight. In the monkey, trypan blue caused abortions with single or two daily doses of 50 mg/kg between 20th to 25th days of pregnancy, but no apparent increase in birth defects (approximately 4,000-fold maximum recommended human dose of 0.75 mg per injection, assuming total absorption). There are no adequate and well-controlled studies in pregnant women. Trypan blue should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.

**8.3 Nursing mothers**

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when trypan blue is administered to a nursing woman.

**8.4 Pediatric use**

The safety and effectiveness of trypan blue have been established in pediatric patients. Use of trypan blue is supported by evidence from an adequate and well-controlled study in pediatric patients.

### 8.5 Geriatric use


No overall differences in safety and effectiveness have been observed between elderly and younger patients.

## 11. Description

MembraneBlue™ 0.15% (trypan blue ophthalmic solution) is a sterile solution of trypan blue (an acid di-azo group dye). MembraneBlue™ 0.15% selectively stains epiretinal membranes during ophthalmic surgical vitrectomy procedures.

Each mL of MembraneBlue™ 0.15% contains: 1.5 mg trypan blue; 1.9 mg sodium monohydrogen orthophosphate ( $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ ); 0.3 mg sodium di-hydrogen orthophosphate ( $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ ); 8.2 mg sodium chloride ( $\text{NaCl}$ ); and water for injection. The pH is 7.3 - 7.6. The osmolality is 257-314 mOsm/kg.

The drug substance trypan blue has the chemical name 3,3'-[(3,3'-dimethyl-4,4'-biphenylene) bis (azo)] bis(5-amino-4-hydroxy-2,7-naphthalenedisulfonic acid) tetra sodium salt, a molecular weight of 960.8, a molecular formula of  $\text{C}_{34}\text{H}_{24}\text{N}_6\text{Na}_4\text{O}_{14}\text{S}_4$ , and has the following chemical structure:



## 12. Clinical Pharmacology

### 12.1 Mechanism of Action

MembraneBlue™ 0.15% selectively stains membranes in the human eye during posterior surgery, such as epiretinal membranes (ERM) and Internal Limiting Membranes (ILM).

## 13. Nonclinical Toxicology

### 13.1 Carcinogenesis, mutagenesis, impairment of fertility

Trypan blue is carcinogenic in rats. Wister/Lewis rats developed lymphomas after receiving subcutaneous injections of 1% trypan blue dosed at 50 mg/kg every other week for 52

weeks (total dose approximately 100,000-fold the maximum recommended human dose of 0.75 mg per injection in a 60 kg person, assuming total absorption).

Trypan blue was mutagenic in the Ames test and caused DNA strand breaks in vitro.

## 16. How Supplied/Storage and Handling

MembraneBlue™ 0.15% is supplied as follows: 0.5 mL of MembraneBlue™ 0.15% in a sterile single-use Luer Lok, 2.25 mL glass syringe, grey rubber plunger stopper and tip cap with polypropylene plunger rod in a peel pouch. Five pouched products are packed in one distribution box.

MembraneBlue™ 0.15% is stored at 15-25°C (59-77°F). Protect from direct sunlight.

### Rx ONLY

*Manufactured by*  
D.O.R.C. International b.v.  
Scheijdelweg 2  
3214 VN Zuidland  
The Netherlands

*Distributed in the United States by*  
Dutch Ophthalmic, USA  
10 Continental Drive, Bldg 1  
Exeter, NH 03833, USA  
Phone: 800-75-DUTCH or 603-778-6929.